AbbVie Reports meta-analysis Data for Danicopan in Hepatitis B

AbbVie today announced meta-analysis results for danicopan in patients with hepatitis B. The study demonstrated that danicopan improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of hepatitis B and support the continued development of danicopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.